Influenza
Conditions
Brief summary
This is a Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of NasoVAX in healthy adults 18 to 49 years of age. Subjects will be screened within 28 days of randomization (Day 1).
Detailed description
This is a Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of NasoVAX in healthy adults 18 to 49 years of age. Subjects will be screened within 28 days of randomization (Day 1). Approximately 60 subjects who meet all inclusion and no exclusion criteria and provide written informed consent will be enrolled into 3 sequential cohorts of 20 subjects each defined by the viral particle dose (1×10(9th), 1×10(10th), and 1×10(11th) vp). Within each cohort and its sentinel group, subjects will be randomized in a 3:1 ratio to receive 1 intranasal dose of NasoVAX or placebo (Day 1). A sentinel group of 5 subjects from each cohort will be dosed and followed through Day 8. Dosing of the remainder of each cohort may proceed if no events meeting stopping criteria have occurred. The SRC, consisting of the Investigator, the Medical Monitor, and a Sponsor Representative, will review AE, reactogenicity, and laboratory data through Day 8 for all subjects in each cohort before subjects are randomized to the next higher dose. If any event meeting stopping criteria occur, the SRC will review all available safety information before additional patients are dosed.
Interventions
BIOLOGICALNasoVAX
Single ascending dose study
Sponsors
Altimmune, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Intervention model description
Single ascending dose study
Eligibility
Sex/Gender
ALL
Age
18 Years to 49 Years
Healthy volunteers
Yes
Inclusion criteria
Subjects who meet all of the following criteria may be included in the study: 1. Men and women 18 to 49 years of age, inclusive 2. Good general health status as determined by the Investigator 3. Adequate venous access for repeated phlebotomies 4. Screening laboratory results within institutional normal range or Grade 1 elevation if the Investigator documents clinical insignificance. Creatine kinase or bilirubin may be Grade 2 if associated with normal alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and the Investigator considers the result not to be clinically significant due to vigorous exercise or Gilbert's syndrome 5. Negative drug and alcohol screen at Screening and predose on Day 1 6. For women who have not been surgically sterilized or have laboratory confirmation of postmenopausal status, negative pregnancy test 7. Willingness to practice a highly effective method of contraception that may include, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with a postmenopausal partner, monogamous relationship with vasectomized partner, vasectomy, surgical sterilization (hysterectomy, or bilateral tubal ligation, salpingectomy, or oophorectomy), licensed hormonal methods, intrauterine device (IUD), or consistent use of a barrier method (eg, condom, diaphragm) with spermicide for 28 days after the NasoVAX/placebo dose 8. Willingness to participate and comply with all aspects of the study through the entire study period, including nasopharyngeal swabs and blood and urine samples 9. Provision of written informed consent Subjects who meet any of the following criteria will be excluded from the study: 1. Pregnant, possibly pregnant, or lactating women 2. Household contacts of pregnant women, children \< 5 years of age, or immunocompromised individuals for the period up through 2 weeks postvaccination 3. Persons who care for pregnant women, children \< 5 years of age, or immunocompromised individuals for the period up through 2 weeks postvaccination 4. Body mass index \> 35.0 kg/m2 5. Positive results for HIV, hepatitis B virus, or hepatitis C virus at Screening 6. Asthma or other chronic lung disease that is greater than mild in severity. Specifically excluded are participants with the any of the following events in the past year: * Daily symptoms * Daily use of short acting beta 2 agonists * Use of inhaled steroids or theophylline * Use of pulse systemic steroids * Emergency care or hospitalization related to asthma or other chronic lung disease * Systemic steroids for asthma exacerbation 7. History of diabetes mellitus (gestational diabetes is allowed if treatment was not required postpartum and serum glucose is currently in the normal range) 8. History of coronary artery disease, arrhythmia, or congestive heart failure 9. Clinically significant ECG abnormality as determined by the Investigator 10. Poorly controlled hypertension (systolic blood pressure \> 150 mmHg or diastolic blood pressure \> 95 mmHg) at Screening or predose on Day 1 11. History of anaphylaxis or angioedema 12. Known allergy to any of the ingredients in the vaccine formulation 13. History of chronic rhinitis, nasal septal defect, cleft palate, nasal polyps, or other nasal abnormality that might affect vaccine administration 14. Previous nasal surgery or nasal cauterization 15. Any symptoms of upper respiratory infection or temperature \> 38°C within 3 days before Day 1 16. Any symptoms within 24 hours before Day 1 of upper respiratory illness of allergy flare-up that, in the opinion of the Investigator, presents as nasal congestion or rhinorrhea that could inhibit the proper administration of the IP 17. Known or suspected malignancy, excluding non-melanoma skin cancers and other early stage surgically excised malignancies that the Investigator considers to be exceedingly unlikely to recur 18. Immunocompromised individuals, including those who have used corticosteroids (including intranasal steroids), alkylating drugs, antimetabolites, radiation, immune-modulating biologics, or other immunomodulating therapies within 90 days before Day 1 or those who plan use during the study period 19. Use of statin medication within 30 days before Day 1 (see list in Section 6.8.1) 20. Receipt of intranasal medications (including over-the-counter medications) within 30 days before Day 1 21. Receipt of any investigational product (IP) within 30 days before Day 1 22. Receipt of any vaccine within 30 days before Day 1 23. Receipt of intranasal vaccine within 90 days before Day 1 24. Receipt of any influenza vaccine within 6 months before Day 1 25. Any change in medication for a chronic medical condition within 30 days before Day 1 26. Past regular use or current use of intranasal illicit drugs 27. Smoking of any type (eg, cigarettes, electronic cigarettes, marijuana) or use of any tobacco product within 30 days before Day 1 28. Any medical, psychiatric, or social condition or occupational or other responsibility that in the judgment of the Investigator would interfere with or serve as a contraindication to protocol adherence, assessment of safety (including reactogenicity), or a subject's ability to give informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | Day 1 to Day 181 | Adverse events (AEs): counts and percentages of subjects with AEs Day 1 to day 29 and Medically attended AEs (MAEs), serious AEs (SAEs), new-onset chronic illnesses (NCIs) from Day 1 to Day 181 |
| Number of Treatment-Emergent Reactogenicity Events in Participants [Safety and Tolerability] | 14-days after vaccination | Reactogenicity: counts and percentages of subjects with 'yes' to any reactogenicity event (nasal irritation, sneezing, nasal congestion, sore throat, change in smell, change in taste, change in vision, eye pain, headache, fatigue, muscle ache, nausea, vomiting, diarrhea, chills, fever) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Seroprotection Rate | Day 1 to Day 29 | The percentage of subjects with an HAI titer greater than or equal to 1:40 |
| Seroconversion Rate | Day 1 to Day 29 | The percentage of subjects with either a baseline HAI titer less than 1:10 and a postvaccination titer greater than or equal to 1:40 or a baseline HAI titer greater than or equal to 1:10 and a 4-fold increase in postvaccination HAI titer relative to baseline |
| Geometric Mean Antibody Level Measured by Hemagglutination Inhibition (HAI) in Serum | Day 1 to Day 29 | The antilog of the mean of the log-transformed antibody titers for humoral immune response to NasoVAX at Day 29 by HAI |
| Antibody Responder Rate by Microneutralization | Day 1 to Day 29 | The percentages of subjects with 2-fold and 4-fold rises from baseline in antibody level measured by microneutralization |
| Antibody Level Measured by Microneutralization in Serum | Day 1 to Day 29 | Geometric mean titer (GMT) for humoral immune response to NasoVAX at Day 29 by microneutralization |
| Geometric Mean Ratio of Postvaccination and Prevaccination Antibody Level Measured by Hemagglutination Inhibition (HAI) in Serum | Day 1 to Day 29 | The ratio of postvaccination and prevaccination geometric mean titers within the same dose group for humoral immune response to NasoVAX at Day 29 by HAI |
Countries
United States
Participant flow
Recruitment details
Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of NasoVAX in healthy adults 18 to 49 years of age. Subjects were screened within 28 days of randomization.
Pre-assignment details
60 subjects who met all inclusion and no exclusion criteria and provided written informed consent were enrolled into 3 sequential cohorts of 20 subjects each defined by the vaccine dose (1×10\^9, 1×10\^10,1×10\^11 vp). Within each cohort and its sentinel group, subjects were randomized in a 3:1 ratio to receive 1 intranasal dose of NasoVAX or placebo
Participants by arm
| Arm | Count |
|---|---|
| NasoVAX Low Dose NasoVAX administered by intranasal spray at a single dose of 1×10\^9viral particles (vp) | 15 |
| NasoVAX Medium Dose NasoVAX administered by intranasal spray at a single dose of 1×10\^10 viral particles (vp) | 15 |
| NasoVAX High Dose NasoVAX administered by intranasal spray at a single dose of 1×10\^11 viral particles (vp) | 15 |
| Placebo Normal saline administered by intranasal spray at a single dose | 15 |
| Total | 60 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Withdrawal by Subject | 0 | 1 | 0 | 0 |
Baseline characteristics
| Characteristic | NasoVAX Low Dose | NasoVAX Medium Dose | NasoVAX High Dose | Placebo | Total |
|---|---|---|---|---|---|
| Age, Categorical Age <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Age >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Age Between 18 and 65 years | 15 Participants | 15 Participants | 15 Participants | 15 Participants | 60 Participants |
| Age, Continuous | 30.1 years | 31.6 years | 32.6 years | 29.3 years | 30.9 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants | 4 Participants | 2 Participants | 0 Participants | 9 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 12 Participants | 11 Participants | 13 Participants | 15 Participants | 51 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 2 Participants | 2 Participants | 0 Participants | 5 Participants |
| Race (NIH/OMB) Black or African American | 5 Participants | 4 Participants | 5 Participants | 6 Participants | 20 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 2 Participants | 1 Participants | 0 Participants | 4 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) White | 7 Participants | 7 Participants | 7 Participants | 9 Participants | 30 Participants |
| Sex: Female, Male Female | 11 Participants | 10 Participants | 6 Participants | 6 Participants | 33 Participants |
| Sex: Female, Male Male | 4 Participants | 5 Participants | 9 Participants | 9 Participants | 27 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 15 | 0 / 15 | 0 / 15 | 0 / 15 |
| other Total, other adverse events | 10 / 15 | 10 / 15 | 10 / 15 | 15 / 15 |
| serious Total, serious adverse events | 0 / 15 | 0 / 15 | 0 / 15 | 0 / 15 |
Outcome results
Primary
Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability]
Adverse events (AEs): counts and percentages of subjects with AEs Day 1 to day 29 and Medically attended AEs (MAEs), serious AEs (SAEs), new-onset chronic illnesses (NCIs) from Day 1 to Day 181
Time frame: Day 1 to Day 181
Population: All ALT-103-201 and ALT-FLZ-401 subjects who provide informed consent, are randomized, and receive at least 1 vaccination. The Safety Population will be used for all safety analyses and will be analyzed according to the treatment received.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| NasoVAX Low Dose | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | Grade 3 or 4 TEAE | 0 Participants |
| NasoVAX Low Dose | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | Serious TEAE | 0 Participants |
| NasoVAX Low Dose | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | TEAE Leading to Withdrawal | 0 Participants |
| NasoVAX Low Dose | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | IP Related TEAE | 2 Participants |
| NasoVAX Low Dose | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | IP Related SAE | 0 Participants |
| NasoVAX Low Dose | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | Any TEAE | 10 Participants |
| NasoVAX Medium Dose | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | IP Related TEAE | 5 Participants |
| NasoVAX Medium Dose | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | Any TEAE | 10 Participants |
| NasoVAX Medium Dose | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | Grade 3 or 4 TEAE | 2 Participants |
| NasoVAX Medium Dose | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | IP Related SAE | 0 Participants |
| NasoVAX Medium Dose | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | TEAE Leading to Withdrawal | 0 Participants |
| NasoVAX Medium Dose | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | Serious TEAE | 0 Participants |
| NasoVAX High Dose | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | TEAE Leading to Withdrawal | 0 Participants |
| NasoVAX High Dose | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | Serious TEAE | 0 Participants |
| NasoVAX High Dose | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | IP Related SAE | 0 Participants |
| NasoVAX High Dose | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | IP Related TEAE | 3 Participants |
| NasoVAX High Dose | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | Any TEAE | 10 Participants |
| NasoVAX High Dose | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | Grade 3 or 4 TEAE | 1 Participants |
| Placebo | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | IP Related TEAE | 3 Participants |
| Placebo | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | Any TEAE | 15 Participants |
| Placebo | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | Serious TEAE | 0 Participants |
| Placebo | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | TEAE Leading to Withdrawal | 0 Participants |
| Placebo | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | IP Related SAE | 0 Participants |
| Placebo | Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | Grade 3 or 4 TEAE | 0 Participants |
Primary
Number of Treatment-Emergent Reactogenicity Events in Participants [Safety and Tolerability]
Reactogenicity: counts and percentages of subjects with 'yes' to any reactogenicity event (nasal irritation, sneezing, nasal congestion, sore throat, change in smell, change in taste, change in vision, eye pain, headache, fatigue, muscle ache, nausea, vomiting, diarrhea, chills, fever)
Time frame: 14-days after vaccination
Population: All ALT-103-201 and ALT-FLZ-401 subjects who provide informed consent, are randomized, and receive at least 1 vaccination. The Safety Population will be used for all safety analyses and will be analyzed according to the treatment received.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| NasoVAX Low Dose | Number of Treatment-Emergent Reactogenicity Events in Participants [Safety and Tolerability] | Any local event | 9 Participants |
| NasoVAX Low Dose | Number of Treatment-Emergent Reactogenicity Events in Participants [Safety and Tolerability] | Any systemic event | 9 Participants |
| NasoVAX Medium Dose | Number of Treatment-Emergent Reactogenicity Events in Participants [Safety and Tolerability] | Any systemic event | 11 Participants |
| NasoVAX Medium Dose | Number of Treatment-Emergent Reactogenicity Events in Participants [Safety and Tolerability] | Any local event | 9 Participants |
| NasoVAX High Dose | Number of Treatment-Emergent Reactogenicity Events in Participants [Safety and Tolerability] | Any local event | 6 Participants |
| NasoVAX High Dose | Number of Treatment-Emergent Reactogenicity Events in Participants [Safety and Tolerability] | Any systemic event | 5 Participants |
| Placebo | Number of Treatment-Emergent Reactogenicity Events in Participants [Safety and Tolerability] | Any local event | 6 Participants |
| Placebo | Number of Treatment-Emergent Reactogenicity Events in Participants [Safety and Tolerability] | Any systemic event | 6 Participants |
Secondary
Antibody Level Measured by Microneutralization in Serum
Geometric mean titer (GMT) for humoral immune response to NasoVAX at Day 29 by microneutralization
Time frame: Day 1 to Day 29
Population: Per-protocol population: All subjects who received the assigned dose of the test article, had HAI assay results on Days 1 and 29, and had no major protocol deviations affecting the primary immunogenicity outcomes.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| NasoVAX Low Dose | Antibody Level Measured by Microneutralization in Serum | 44.9 Titer |
| NasoVAX Medium Dose | Antibody Level Measured by Microneutralization in Serum | 113.1 Titer |
| NasoVAX High Dose | Antibody Level Measured by Microneutralization in Serum | 142.5 Titer |
| Placebo | Antibody Level Measured by Microneutralization in Serum | 17.8 Titer |
Secondary
Antibody Responder Rate by Microneutralization
The percentages of subjects with 2-fold and 4-fold rises from baseline in antibody level measured by microneutralization
Time frame: Day 1 to Day 29
Population: Per-protocol population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| NasoVAX Low Dose | Antibody Responder Rate by Microneutralization | Percentage of subjects with 2-fold rise | 40.0 percentage of participants |
| NasoVAX Low Dose | Antibody Responder Rate by Microneutralization | Percentage of subjects with 4-fold rise | 13.3 percentage of participants |
| NasoVAX Medium Dose | Antibody Responder Rate by Microneutralization | Percentage of subjects with 4-fold rise | 26.7 percentage of participants |
| NasoVAX Medium Dose | Antibody Responder Rate by Microneutralization | Percentage of subjects with 2-fold rise | 46.7 percentage of participants |
| NasoVAX High Dose | Antibody Responder Rate by Microneutralization | Percentage of subjects with 2-fold rise | 73.3 percentage of participants |
| NasoVAX High Dose | Antibody Responder Rate by Microneutralization | Percentage of subjects with 4-fold rise | 53.3 percentage of participants |
| Placebo | Antibody Responder Rate by Microneutralization | Percentage of subjects with 2-fold rise | 0.0 percentage of participants |
| Placebo | Antibody Responder Rate by Microneutralization | Percentage of subjects with 4-fold rise | 0.0 percentage of participants |
Comparison: NasoVAX low dose vs placebop-value: 0.0169Fisher Exact
Comparison: NasoVAX medium dose vs placebop-value: 0.0063Fisher Exact
Comparison: NasoVAX high dose vs placebop-value: <0.0001Fisher Exact
Secondary
Geometric Mean Antibody Level Measured by Hemagglutination Inhibition (HAI) in Serum
The antilog of the mean of the log-transformed antibody titers for humoral immune response to NasoVAX at Day 29 by HAI
Time frame: Day 1 to Day 29
Population: Per-protocol population: All subjects who received the assigned dose of the test article, had HAI assay results on Days 1 and 29, and had no major protocol deviations affecting the primary immunogenicity outcomes.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| NasoVAX Low Dose | Geometric Mean Antibody Level Measured by Hemagglutination Inhibition (HAI) in Serum | 87.2 Titer |
| NasoVAX Medium Dose | Geometric Mean Antibody Level Measured by Hemagglutination Inhibition (HAI) in Serum | 136.1 Titer |
| NasoVAX High Dose | Geometric Mean Antibody Level Measured by Hemagglutination Inhibition (HAI) in Serum | 164.0 Titer |
| Placebo | Geometric Mean Antibody Level Measured by Hemagglutination Inhibition (HAI) in Serum | 31.3 Titer |
Secondary
Geometric Mean Ratio of Postvaccination and Prevaccination Antibody Level Measured by Hemagglutination Inhibition (HAI) in Serum
The ratio of postvaccination and prevaccination geometric mean titers within the same dose group for humoral immune response to NasoVAX at Day 29 by HAI
Time frame: Day 1 to Day 29
Population: Per-protocol population
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| NasoVAX Low Dose | Geometric Mean Ratio of Postvaccination and Prevaccination Antibody Level Measured by Hemagglutination Inhibition (HAI) in Serum | 2.1 Ratio |
| NasoVAX Medium Dose | Geometric Mean Ratio of Postvaccination and Prevaccination Antibody Level Measured by Hemagglutination Inhibition (HAI) in Serum | 2.2 Ratio |
| NasoVAX High Dose | Geometric Mean Ratio of Postvaccination and Prevaccination Antibody Level Measured by Hemagglutination Inhibition (HAI) in Serum | 4.3 Ratio |
| Placebo | Geometric Mean Ratio of Postvaccination and Prevaccination Antibody Level Measured by Hemagglutination Inhibition (HAI) in Serum | 0.9 Ratio |
Secondary
Seroconversion Rate
The percentage of subjects with either a baseline HAI titer less than 1:10 and a postvaccination titer greater than or equal to 1:40 or a baseline HAI titer greater than or equal to 1:10 and a 4-fold increase in postvaccination HAI titer relative to baseline
Time frame: Day 1 to Day 29
Population: Per-protocol population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| NasoVAX Low Dose | Seroconversion Rate | 13.3 percentage of participants |
| NasoVAX Medium Dose | Seroconversion Rate | 26.7 percentage of participants |
| NasoVAX High Dose | Seroconversion Rate | 33.3 percentage of participants |
| Placebo | Seroconversion Rate | 0.0 percentage of participants |
p-value: 0.4828Fisher Exact
p-value: 0.0996Fisher Exact
p-value: 0.0421Fisher Exact
Secondary
Seroprotection Rate
The percentage of subjects with an HAI titer greater than or equal to 1:40
Time frame: Day 1 to Day 29
Population: Per-protocol population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| NasoVAX Low Dose | Seroprotection Rate | 80.0 percentage of participants |
| NasoVAX Medium Dose | Seroprotection Rate | 100 percentage of participants |
| NasoVAX High Dose | Seroprotection Rate | 100 percentage of participants |
| Placebo | Seroprotection Rate | 53.3 percentage of participants |
p-value: 0.2451Fisher Exact
p-value: 0.0063Fisher Exact
p-value: 0.0063Fisher Exact